Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Abstract Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the
effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that …
effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that …
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
The full-length prefusion-stabilized SARS-CoV-2 spike (S) is the principal antigen of COVID-
19 vaccines. Vaccine efficacy has been impacted by emerging variants of concern that …
19 vaccines. Vaccine efficacy has been impacted by emerging variants of concern that …
Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires
YA Lomakin, LA Ovchinnikova, SS Terekhov… - Communications …, 2024 - nature.com
Identifying high-affinity antibodies in human serum is challenging due to extremely low
number of circulating B cells specific to the desired antigens. Delays caused by a lack of …
number of circulating B cells specific to the desired antigens. Delays caused by a lack of …
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults
According to the WHO target product profile for COVID-19 vaccines, the vaccine in
development should be indicated for active immunisation in all populations. Therefore, PT …
development should be indicated for active immunisation in all populations. Therefore, PT …